Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course weekly risedronate to prevent steroid-associated bone loss in inflammatory bowel disease flare
2004-004325-10Phase 4Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of risedronate in glucocorticoid-induced osteoporosis (GIOP) and inflammatory bowel disease (IBD) (2 arms), sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoint: Bone mineral density change. Started Jun 2005; status: completed.
02
Drugs
risedronate
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2004-004325-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004325-10.